MD960288A - Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare - Google Patents

Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare

Info

Publication number
MD960288A
MD960288A MD96-0288A MD960288A MD960288A MD 960288 A MD960288 A MD 960288A MD 960288 A MD960288 A MD 960288A MD 960288 A MD960288 A MD 960288A
Authority
MD
Moldova
Prior art keywords
dnase
separating
pharmaceutical composition
forms
human
Prior art date
Application number
MD96-0288A
Other languages
English (en)
Russian (ru)
Inventor
John Frenz
Steven J. Shire
Mary B. Sliwkowski
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of MD960288A publication Critical patent/MD960288A/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Prezenta invenţie se referă la identificarea şi caracterizarea a două componente ale preparatului DNazei recombinante. Aceste componente reprezintă DNaza umană purificată dezaminată şi DNaza umană purificată nedezaminată. În prezenta invenţie sunt studiate metodele de separare a acestor componente şi utilizarea în scopuri farmaceutice a formei nedezaminate, în special în componenţa compoziţiilor, atunci când formele sunt situate în fiole de masă plastică, pentru administrare pacienţilor care suferă de dereglări cu caracter pulmonar.
MD96-0288A 1992-06-08 1993-05-28 Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare MD960288A (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE
PCT/US1993/005136 WO1993025670A1 (en) 1992-06-08 1993-05-28 Purified forms of dnase

Publications (1)

Publication Number Publication Date
MD960288A true MD960288A (ro) 1998-01-31

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0288A MD960288A (ro) 1992-06-08 1993-05-28 Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare

Country Status (30)

Country Link
US (4) US5279823A (ro)
EP (2) EP0644932B1 (ro)
JP (1) JP3383307B2 (ro)
KR (2) KR100302092B1 (ro)
AT (2) ATE195340T1 (ro)
AU (1) AU682822B2 (ro)
BG (1) BG62335B1 (ro)
BR (1) BR9306670A (ro)
CA (1) CA2137237C (ro)
CZ (1) CZ293105B6 (ro)
DE (3) DE69334317D1 (ro)
DK (1) DK0644932T3 (ro)
ES (1) ES2150447T3 (ro)
FI (1) FI945549A (ro)
GB (1) GB2282140B (ro)
GE (1) GEP20002300B (ro)
GR (1) GR3034718T3 (ro)
HU (1) HU219549B (ro)
IL (1) IL105724A (ro)
MD (1) MD960288A (ro)
NO (1) NO318644B1 (ro)
NZ (1) NZ253559A (ro)
PL (1) PL175873B1 (ro)
PT (1) PT644932E (ro)
RO (1) RO117188B1 (ro)
RU (1) RU2238320C2 (ro)
SK (1) SK282957B6 (ro)
TJ (1) TJ396B (ro)
UA (1) UA46693C2 (ro)
WO (1) WO1993025670A1 (ro)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853121B1 (en) * 1988-12-23 2007-03-28 Genentech, Inc. Human DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1995023613A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
US6383788B1 (en) * 1994-03-04 2002-05-07 Genentech, Inc. Minimizing thermally induced aggregation of DNase in solution with calcium
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
EP0817839A1 (en) * 1994-05-05 1998-01-14 Human Genome Sciences, Inc. Human dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
US5821103A (en) * 1994-09-06 1998-10-13 Tanuma; Sei-Ichi Deoxyribonuclease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
ATE332379T1 (de) * 1996-02-05 2006-07-15 Genentech Inc Menschliche dnase resistent gegen actininhibitoren
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
IL139035A0 (en) * 1998-05-06 2001-11-25 Genentech Inc Protein purification by ion exchange chromatography
NZ521051A (en) * 2000-02-11 2003-07-25 Profile Respiratory Systems Lt Drug delivery apparatus
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
DE60135983D1 (de) * 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
ES2629602T5 (es) 2002-09-11 2021-06-08 Genentech Inc Purificación de proteínas
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
WO2007143206A2 (en) * 2006-06-02 2007-12-13 Epicentre Technologies Compositions and methods for removal of dna from a sample
PT2086642E (pt) 2006-10-18 2014-09-30 Periness Ltd Dnase para o tratamento de subfertilidade masculina
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
GB2474225A (en) * 2009-07-21 2011-04-13 Biotec Pharmacon Asa DNase for decontamination of reverse transcription and amplification reactions
EP3318635A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
RU2017101727A (ru) * 2014-06-25 2018-07-25 ДжейЭйчЭл БИОТЕК, ИНК. Способы и реагенты для очистки белков
EP3214172B1 (en) 2014-10-31 2019-02-13 JCR Pharmaceuticals CO., LTD. Method for producing remcombinant human dnasei
WO2017019876A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MX2019005617A (es) 2016-11-17 2019-08-14 Iovance Biotherapeutics Inc Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
WO2021244964A1 (en) 2020-06-01 2021-12-09 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
EP0853121B1 (en) * 1988-12-23 2007-03-28 Genentech, Inc. Human DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor

Also Published As

Publication number Publication date
SK149594A3 (en) 1996-01-10
WO1993025670A1 (en) 1993-12-23
FI945549A0 (fi) 1994-11-25
TJ396B (en) 2004-12-29
RU2238320C2 (ru) 2004-10-20
EP0644932B1 (en) 2000-08-09
GB2282140B (en) 1996-04-17
DE69329200D1 (de) 2000-09-14
RU94046424A (ru) 1997-03-10
IL105724A0 (en) 1993-09-22
FI945549A (fi) 1994-11-25
CA2137237C (en) 2004-10-26
HUT70468A (en) 1995-10-30
EP1013284A3 (en) 2000-08-30
BG62335B1 (bg) 1999-08-31
NO318644B1 (no) 2005-04-25
NZ253559A (en) 1996-11-26
HU9403512D0 (en) 1995-02-28
US6440412B1 (en) 2002-08-27
NO944752D0 (no) 1994-12-08
US5279823A (en) 1994-01-18
BG99234A (bg) 1995-07-28
ATE195340T1 (de) 2000-08-15
GR3034718T3 (en) 2001-01-31
ES2150447T3 (es) 2000-12-01
UA46693C2 (uk) 2002-06-17
ATE455557T1 (de) 2010-02-15
CA2137237A1 (en) 1993-12-23
AU682822B2 (en) 1997-10-23
PL175873B1 (pl) 1999-02-26
EP1013284A2 (en) 2000-06-28
BR9306670A (pt) 1998-12-08
KR100302092B1 (ko) 2001-10-22
IL105724A (en) 1997-06-10
AU4398193A (en) 1994-01-04
US5783433A (en) 1998-07-21
KR100323357B1 (ko) 2002-02-19
PT644932E (pt) 2001-02-28
SK282957B6 (sk) 2003-01-09
EP1013284B1 (en) 2010-01-20
RO117188B1 (ro) 2001-11-30
US20030077267A1 (en) 2003-04-24
GB2282140A (en) 1995-03-29
GEP20002300B (en) 2000-11-25
CZ293105B6 (cs) 2004-02-18
HU219549B (hu) 2001-05-28
US6932965B2 (en) 2005-08-23
NO944752L (no) 1994-12-08
EP0644932A1 (en) 1995-03-29
DE4392749T1 (de) 1995-07-20
GB9423695D0 (en) 1995-01-11
CZ303294A3 (en) 1995-06-14
DE69334317D1 (de) 2010-03-11
DE69329200T2 (de) 2001-04-26
JP3383307B2 (ja) 2003-03-04
DK0644932T3 (da) 2001-01-02
JPH07507455A (ja) 1995-08-24

Similar Documents

Publication Publication Date Title
MD960288A (ro) Metodă de separare a formelor DNazei, DNaza omului, compoziţie farmaceutică, metodă de păstrare a DNazei, metodă de tratare
EP0682526A4 (en) LENGTH ADMINISTRATION OF SCR1 AND OTHER COMPLEMENT INHIBITORS.
HUT41809A (en) Process for preparing dideoxy-nucleosides and pharmaceutical compositions containing such compounds
MY117892A (en) Therapeutic compounds
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
CA2123049A1 (en) Pharmaceutical containing the p40 subunit of interleukin 12
HUP0104410A2 (hu) Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények
CA1188218A (en) PURIFIED ANTINEOPLASTIC FRACTIONS AND METHODS OF TREATMENT OF NEOPLASMS
GR861803B (en) Novel carbonic acid derivatives method for their preparation their use and medicine containing them
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
NZ330944A (en) Peptide derivatives
MX9805441A (es) Compuestos terapeuticos.
DE3068820D1 (en) Pharmaceutical preparations
MY104124A (en) Therapeutic compounds.
HU9300244D0 (en) Method for producing chemotherapeutical agent of antitumourous effect originated of plants and medical preparatives containing it
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
DE69420574D1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
ATE181239T1 (de) Verwendung von biertreberextrakt zur herstellung von oral zu verabreichenden zubereitungen

Legal Events

Date Code Title Description
PD99 Pending application